Short answer
Schrodinger, Inc. (SDGR) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 7.01 (Regulation FD Disclosure). $57 million cash payment received upon Eli Lilly’s completion of Ajax Therapeutics acquisition.
Schrodinger, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- $57 million cash payment received upon Eli Lilly’s completion of Ajax Therapeutics acquisition
- Additional cash milestone payments remain possible based on Ajax clinical and regulatory achievements
- Immediate liquidity benefit with potential future upside from Ajax’s development progress
- Disclosure furnished under Regulation FD, limiting Exchange Act Section 18 liability calcification
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Schrodinger, Inc. 8-K filings
Get the next SDGR 8-K as it lands
Follow SDGR for push alerts, or ask the research agent what this filing means.